Given the increasing biological complexity of combination drug therapies in treating ccRCC, in which additive or potentially synergistic effects may influence their combined efficacy8,16, it is essential to first gain insight into the biology underlying response and resistance to anti-PD-1 monotherapy in order to better understand the effects of these drugs in combination. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.